NO20012017L - Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose - Google Patents

Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose

Info

Publication number
NO20012017L
NO20012017L NO20012017A NO20012017A NO20012017L NO 20012017 L NO20012017 L NO 20012017L NO 20012017 A NO20012017 A NO 20012017A NO 20012017 A NO20012017 A NO 20012017A NO 20012017 L NO20012017 L NO 20012017L
Authority
NO
Norway
Prior art keywords
vegf
gene
protein
prevent restenosis
growth factor
Prior art date
Application number
NO20012017A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012017D0 (no
Inventor
Kari Alitalo
Mikko O Hiltunen
Markku M Jeltsch
Marc G Achen
Original Assignee
Licentia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Ltd filed Critical Licentia Ltd
Publication of NO20012017D0 publication Critical patent/NO20012017D0/no
Publication of NO20012017L publication Critical patent/NO20012017L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20012017A 1998-10-26 2001-04-24 Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose NO20012017L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10558798P 1998-10-26 1998-10-26
PCT/US1999/024054 WO2000024412A2 (en) 1998-10-26 1999-10-26 Use of vegf-c or vegf-d gene or protein to prevent restenosis

Publications (2)

Publication Number Publication Date
NO20012017D0 NO20012017D0 (no) 2001-04-24
NO20012017L true NO20012017L (no) 2001-06-26

Family

ID=22306672

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012017A NO20012017L (no) 1998-10-26 2001-04-24 Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose

Country Status (12)

Country Link
EP (1) EP1126870B1 (enExample)
JP (2) JP4769929B2 (enExample)
CN (1) CN1338943A (enExample)
AT (1) ATE275417T1 (enExample)
AU (1) AU768330B2 (enExample)
CA (1) CA2340593C (enExample)
DE (1) DE69920031T2 (enExample)
ES (1) ES2229788T3 (enExample)
NO (1) NO20012017L (enExample)
NZ (1) NZ510121A (enExample)
PT (1) PT1126870E (enExample)
WO (1) WO2000024412A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
JP4981229B2 (ja) 2000-02-25 2012-07-18 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ハイブリッド血管内皮成長因子ＤＮＡｓおよびタンパク質に関与する物質および方法
AU2001268149B2 (en) * 2000-06-01 2005-08-18 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
MXPA02003434A (es) 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
DK2314293T3 (en) 2001-01-16 2017-04-18 Vascular Therapies Llc IMPLANTABLE DEVICE CONTAINING RESORBABLE MATERIAL MATERIAL AND RAPAMYCINE FOR PREVENTION OR TREATMENT OF VASCULOPROLIFERATIVE DISEASES
MXPA03009408A (es) 2001-04-13 2004-01-29 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
FI20010898A0 (fi) * 2001-04-30 2001-04-30 Ylae Herttuala Seppo Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi
GB0120690D0 (en) 2001-08-24 2001-10-17 Novartis Ag Organic compounds
BR0309676A (pt) * 2002-04-30 2005-02-22 Fit Biotech Oyl Plc Dispositivo médico
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
US20070254956A1 (en) * 2003-10-29 2007-11-01 Koichi Shudo Medicament for Therapeutic and/or Preventive Treatment of Restenosis or Reocclusion After Vascular Recanalization Operation
JP4832290B2 (ja) * 2004-03-18 2011-12-07 健輔 江頭 薬剤・遺伝子溶出型ステント
EP1919944B1 (en) 2005-08-15 2011-03-23 Vegenics Pty Ltd Modified vegf and pdgf with improved angiogenic properties
CA2663547C (en) 2006-09-22 2020-08-25 Orthologic Corp. Method of treating endothelial dysfunction
JP2011512408A (ja) 2008-02-19 2011-04-21 セラドン・コーポレーション 心筋層へのウイルスベクターの取り込みを増大させるための組成物
CN101361988B (zh) * 2008-09-12 2011-12-21 西南交通大学 一种具有生物相容性的血管支架或心脏瓣膜表面涂层的制备方法
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒
CA3131428A1 (en) * 2019-03-29 2020-10-08 Jerald Wayne CURRAN Systems and methods for left ventricular unloading in biologic therapy or vectored gene therapy
CN119454907A (zh) * 2025-01-09 2025-02-18 浙江大学 Vegf-c156s在制备减轻静脉移植物狭窄的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
DE69734359T2 (de) * 1996-08-23 2006-07-06 Ludwig Institute For Cancer Research Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
WO1998049300A2 (en) * 1997-04-25 1998-11-05 Collateral Therapeutics Truncated vegf-related proteins

Also Published As

Publication number Publication date
JP5231587B2 (ja) 2013-07-10
CA2340593C (en) 2012-05-08
WO2000024412A3 (en) 2000-08-03
EP1126870A2 (en) 2001-08-29
CN1338943A (zh) 2002-03-06
NO20012017D0 (no) 2001-04-24
DE69920031D1 (de) 2004-10-14
AU768330B2 (en) 2003-12-11
DE69920031T2 (de) 2005-09-22
PT1126870E (pt) 2005-01-31
NZ510121A (en) 2003-02-28
WO2000024412A2 (en) 2000-05-04
EP1126870B1 (en) 2004-09-08
ATE275417T1 (de) 2004-09-15
JP2002528420A (ja) 2002-09-03
AU1314700A (en) 2000-05-15
JP4769929B2 (ja) 2011-09-07
CA2340593A1 (en) 2000-05-04
ES2229788T3 (es) 2005-04-16
JP2011173874A (ja) 2011-09-08

Similar Documents

Publication Publication Date Title
NO20012017L (no) Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose
Chua et al. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells
Lau et al. TRE17/ubiquitin-specific protease 6 (USP6) oncogene translocated in aneurysmal bone cyst blocks osteoblastic maturation via an autocrine mechanism involving bone morphogenetic protein dysregulation
Hultgårdh-Nilsson et al. Regulated expression of the ets-1 transcription factor in vascular smooth muscle cells in vivo and in vitro
ATE163046T1 (de) Genetische veränderung von endothelzellen
Kallassy et al. Patched (ptch)-associated preferential expression of smoothened (smoh) in human basal cell carcinoma of the skin
ATE269402T1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
WO1998049300A3 (en) Truncated vegf-related proteins
BRPI9809387B8 (pt) anticorpo humanizado anti-fator de crescimento endotelial vascular humano e composição que o compreende
SE8902532D0 (sv) Bestaemning av plasmaproteiner
NO881670L (no) Diagnostisk proeve paa inhibitor for plasminogenaktivatorerav vev- og urokinasetype, samt gen som koder for inhibitoren.
CA2295040A1 (en) Method for coating stents with dna and expression of recombinant genes from dna coated stent in vivo
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
WO2003039491A8 (en) Novel isoforms of vascular endothelial cell growth inhibitor
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ATE265526T1 (de) Genetisch veränderte fibroblasten und ihre verwendung
NO20006026L (no) Fremgangsmåter og blandinger for modulering av angiogenese ved bruk av tyrosin kinase SRC
DK1095032T3 (da) Hidtil ukendte fluorescerende CYP2D-assayreagenser
DE60017924D1 (de) Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose
ATE226638T1 (de) Retroviraler vektor und dessen verwendung in gentherapie
Guzman et al. Early and sustained medial cell activation after aortocaval fistula creation in mice
ATE363072T1 (de) Monoklonaler antikörper gegen mxa und mxb
BG105682A (en) Bone stimulating factor
DE59611330D1 (de) Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen